Inflammatory and Immune Biomarkers in Mood Disorders: From Mechanistic Pathways to Clinical Translation
Cells · 08.10.2025 · 14 (19) · 1558
DOI: 10.3390/cells14191558 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 08.10.2025. Verfasst von Mario Pinzi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, School of Medicine, University of Siena, 53100 Siena, Italy. Hauptthemen laut MEDLINE: Mood Disorders, Biomarkers, Neuroinflammatory Diseases, Immune System. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Over the past two decades, immune–inflammatory dysregulation has emerged as a central paradigm in the biology of mood disorders. Patients with major depression (MDD) and bipolar disorder (BD) frequently display low-grade systemic inflammation. Elevated C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) identify clinically relevant subgroups of patients characterized by greater severity, cognitive impairment, and poor treatment response. Changes in the gut microbiota and disruptions of the blood–brain barrier (BBB) act as important gateways through which systemic immune activity can influence the brain. At the intracellular level, pattern-recognition receptors activate convergent hubs including NF-κB, JAK/STAT, and MAPK cascades, while the NLRP3 inflammasome integrates mitochondrial dysfunction and oxidative stress with IL-1β release and pyroptosis. These pathways converge on glial dysregulation, impaired BDNF/TrkB signaling, and kynurenine pathway (KP) alterations, fostering excitotoxicity and synaptic deficits. Translational studies demonstrate that elevated CRP and IL-6 predict poor antidepressant outcomes. Anti-inflammatory agents such as infliximab and celecoxib show efficacy in specific subgroups of patients. Emerging multi-omics approaches identify immuno-metabolic biotypes, supporting the rationale for biomarker-guided stratification. These findings define an ‘inflammatory biotype’ of mood disorders and highlight the need for biomarkers and precision-based trials to guide treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine, School of Medicine, University of Siena, 53100 Siena, Italy.
ORCID-Profile: Andrea Fagiolini, Despoina Koukouna, Giacomo Gualtieri, Simone Pardossi, Alessandro Cuomo
Zitieren
APA
Pinzi, M., Fagiolini, A., Koukouna, D., Gualtieri, G., Rescalli, M. B., Pierini, C., Pardossi, S., Patrizio, B., & Cuomo, A. (2025). Inflammatory and Immune Biomarkers in Mood Disorders: From Mechanistic Pathways to Clinical Translation. Cells, 14(19), 1558. https://doi.org/10.3390/cells14191558
Vancouver
Pinzi M, Fagiolini A, Koukouna D, Gualtieri G, Rescalli MB, Pierini C, et al. Inflammatory and Immune Biomarkers in Mood Disorders: From Mechanistic Pathways to Clinical Translation. Cells. 2025;14(19):1558. doi:10.3390/cells14191558
BibTeX
@article{Pinzi2025,
author = {Pinzi, Mario and Fagiolini, Andrea and Koukouna, Despoina and Gualtieri, Giacomo and Rescalli, Maria Beatrice and Pierini, Caterina and Pardossi, Simone and Patrizio, Benjamin and Cuomo, Alessandro},
title = {Inflammatory and Immune Biomarkers in Mood Disorders: From Mechanistic Pathways to Clinical Translation},
journal = {Cells},
year = {2025},
volume = {14},
number = {19},
pages = {1558},
doi = {10.3390/cells14191558}
}
EUVIMED